| abstract |
Arylglycinamide derivatives represented by a general formula (I) (see formula I ) (wherein Ar denotes a phenyl group which may have 1 to 3 substituents or naphthyl group which may have 1 to 3 substituents, R1 and R4 denote identically or differently hydrogen atoms or lower alkyl groups with 1 to 3 carbon at-oms, R2 denotes a lower alkyl group with 1 to 6 carbon at-oms, cycloalkyl group with 3 to 6 carbon atoms, lower alkyl group with 1 to 4 carbon atoms which may have a phenyl group which may have 1 to 3 substituents, norbornyl group, adamantyl group or phenyl group which may have 1 to 3 substituents, R3 denotes a hydrogen atom or lower alkyl group with 1 to 6 carbon atoms or it may form a ring consti-tuting alkylene together with R2, R5 denotes a lower alkyl group with 1 to 6 carbon atoms or cycloalkyl group with 5 or 6 carbon atoms, R6 denotes a hydrogen atom or lower alkyl group with 1 to 6 carbon atoms or it may form a ring consti-tuting alkylene together with R5, and m denotes 2 or 3), and their salts, which function as effective therapeutic drugs for the dysurias such as urinary incontinence and pol-lakiuria, and the preparative processes therefor are pre-sented. |